Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With First-Line Osimertinib Treatment and Harbor a C797S Mutation

NCT06868485 is registered in ClinicalTrials.gov with Wayshine Biopharm, Inc. as lead sponsor.

NCT NCT06868485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06868485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With First-Line Osimertinib Treatment and Harbor a C797S Mutation
Lead sponsor
Wayshine Biopharm, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 18, 2025
Completion date
December 31, 2027
Enrollment
40 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer